Inventor · disambiguated record
Petra Budde
Also filed as: BUDDE PETRA
5 granted patents·8 pending applications·0 citations·filing 2006–2020
61Inventor score
Top patents by PatentIndex Score
13 records- 0161US11609237B2Marker sequences for diagnosing and stratifying systemic sclerosis patientsONCIMMUNE GERMANY GMBH·Filed 2019·Granted Mar 21, 2023·0 cites·11 claims
- 0255US11860162B2Marker sequences for diagnosing and stratifying SLE patientsONCIMMUNE GERMANY GMBH·Filed 2020·Granted Jan 2, 2024·0 cites·9 claims
- 0351US10571477B2Marker sequences for diagnosing and stratifying systemic sclerosis patientsPROTAGEN AG·Filed 2015·Granted Feb 25, 2020·0 cites·11 claims
- 0443US10746735B2Marker sequences for diagnosing and stratifying SLE patientsPROTAGEN AG·Filed 2015·Granted Aug 18, 2020·0 cites·4 claims
- 0543US2007037143A1Method for screening for protease modulatorsDIGILAB BIOVISION GMBH·Filed 2006·Application pending·0 cites
- 0640US2022317125A1Melanoma biomarkersONCIMMUNE GERMANY GMBH·Filed 2020·Application pending·0 cites
- 0737US2021231663A1Melanoma checkpoint inhibitor detection and treatmentONCIMMUNE GERMANY GMBH·Filed 2018·Application pending·0 cites
- 0836US2020150117A1Immuno-oncology for the treatment of cancerONCIMMUNE GERMANY GMBH·Filed 2018·Application pending·0 cites
- 0935US2019128884A1Marker sequences for managing the therapy of rheumatoid arthritis patientsPROTAGEN AG·Filed 2017·Application pending·0 cites
- 1033US2014242599A1Materials and methods for determining sensitivity potential of compoundsBUDDE PETRA·Filed 2012·Application pending·0 cites
- 1132US2014220566A1Materials and methods for determining sensitivity potential of compoundsLAHERT EMMA·Filed 2012·Application pending·0 cites
- 1232US2019120834A1Marker sequences for rheumatoid arthritisPROTAGEN AG·Filed 2017·Application pending·0 cites
- 1328US10677795B2Marker sequences for the diagnosis and stratification of systemic sclerosis patientsPROTAGEN AG·Filed 2015·Granted Jun 9, 2020·0 cites·9 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →